Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Li J, Guo C, Steinauer N, Zhang J.

Front Biol (Beijing). 2016 Aug;11(4):285-304. doi: 10.1007/s11515-016-1415-1. Epub 2016 Sep 3.

2.

IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells.

Chen X, Zheng J, Zou Y, Song C, Hu X, Zhang CC.

J Hematol Oncol. 2013 Oct 8;6(1):72. doi: 10.1186/1756-8722-6-72.

3.

RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.

Lam K, Zhang DE.

Front Biosci (Landmark Ed). 2012 Jan 1;17:1120-39. Review.

4.

Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity.

Lambert QT, Pradhan A, Roll JD, Reuther GW.

Biochem J. 2011 Aug 15;438(1):155-64. doi: 10.1042/BJ20110351.

5.

Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud Ø.

J Biomed Biotechnol. 2011;2011:104631. doi: 10.1155/2011/104631. Epub 2011 May 3.

6.

In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.

Abdul-Nabi AM, Yassin ER, Varghese N, Deshmukh H, Yaseen NR.

PLoS One. 2010 Aug 27;5(8):e12464. doi: 10.1371/journal.pone.0012464.

7.

Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells.

Rao R, Nalluri S, Fiskus W, Balusu R, Joshi A, Mudunuru U, Buckley KM, Robbins K, Ustun C, Reuther GW, Bhalla KN.

Mol Cancer Ther. 2010 Aug;9(8):2232-42. doi: 10.1158/1535-7163.MCT-10-0336. Epub 2010 Jul 27.

8.

AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.

Dunne J, Gascoyne DM, Lister TA, Brady HJ, Heidenreich O, Young BD.

Cancer Res. 2010 May 15;70(10):3985-95. doi: 10.1158/0008-5472.CAN-09-3604. Epub 2010 May 11.

9.

POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature.

Fortier JM, Payton JE, Cahan P, Ley TJ, Walter MJ, Graubert TA.

Leukemia. 2010 May;24(5):950-7. doi: 10.1038/leu.2010.61. Epub 2010 Apr 8.

10.

Post-translational modifications of Runx1 regulate its activity in the cell.

Wang L, Huang G, Zhao X, Hatlen MA, Vu L, Liu F, Nimer SD.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):30-4. doi: 10.1016/j.bcmd.2009.03.005. Epub 2009 Apr 21. Review.

11.

High-affinity neurotrophin receptors and ligands promote leukemogenesis.

Li Z, Beutel G, Rhein M, Meyer J, Koenecke C, Neumann T, Yang M, Krauter J, von Neuhoff N, Heuser M, Diedrich H, Göhring G, Wilkens L, Schlegelberger B, Ganser A, Baum C.

Blood. 2009 Feb 26;113(9):2028-37. doi: 10.1182/blood-2008-05-155200. Epub 2008 Dec 4.

12.

AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.

Gardini A, Cesaroni M, Luzi L, Okumura AJ, Biggs JR, Minardi SP, Venturini E, Zhang DE, Pelicci PG, Alcalay M.

PLoS Genet. 2008 Nov;4(11):e1000275. doi: 10.1371/journal.pgen.1000275. Epub 2008 Nov 28.

13.

A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects.

Wouters BJ, Löwenberg B, Delwel R.

Blood. 2009 Jan 8;113(2):291-8. doi: 10.1182/blood-2008-04-153239. Epub 2008 Aug 14. Review.

14.

XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors.

Hackanson B, Becker H, Berg T, Binder M, Dierks C, Duque-Afonso J, Lairmore MD, Schäfer HS, Schnitzler M, Zeiser R, Martens U, Mertelsmann R, Lübbert M.

Cancer Res. 2008 Jul 15;68(14):5512-8. doi: 10.1158/0008-5472.CAN-07-6859. No abstract available.

15.

Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

Tam WF, Gu TL, Chen J, Lee BH, Bullinger L, Fröhling S, Wang A, Monti S, Golub TR, Gilliland DG.

Blood. 2008 Sep 1;112(5):1981-92. doi: 10.1182/blood-2007-07-103010. Epub 2008 Jun 17.

16.

Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway.

Hoskins EE, Gunawardena RW, Habash KB, Wise-Draper TM, Jansen M, Knudsen ES, Wells SI.

Oncogene. 2008 Aug 14;27(35):4798-808. doi: 10.1038/onc.2008.121. Epub 2008 Apr 28.

17.

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.

Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T, Ries RE, Lubman O, Fremont DH, McLellan MD, Payton JE, Westervelt P, DiPersio JF, Link DC, Walter MJ, Graubert TA, Watson M, Baty J, Heath S, Shannon WD, Nagarajan R, Bloomfield CD, Mardis ER, Wilson RK, Ley TJ.

Blood. 2008 May 1;111(9):4797-808. doi: 10.1182/blood-2007-09-113027. Epub 2008 Feb 12.

18.

Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells.

Jankovic V, Ciarrocchi A, Boccuni P, DeBlasio T, Benezra R, Nimer SD.

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1260-5. Epub 2007 Jan 16.

19.

Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation.

Elagib KE, Goldfarb AN.

Cancer Lett. 2007 Jun 28;251(2):179-86. Epub 2006 Nov 27. Review.

20.

Supplemental Content

Support Center